Clinical Trials ProgressThe SYN-2510 1L NSCLC chemo combo trial has begun dosing with plans to escalate and enroll around 60 patients by the end of the year, indicating progress in clinical trials.
Market PotentialIncreased investor interest in the PD-1xVEGF space is seen as supportive of building enthusiasm for the mechanism, with Instil shares expected to rise as enthusiasm grows.
Potential AcquisitionInstil Bio is seen as a potential target for acquisition as more players enter the PD-1/L1 x VEGF market.